Skip to main content
SpringerLink
Log in

Brugada syndrome: Recent advances and controversies

  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

The Brugada syndrome, first described as a new clinical entity in 1992, is widely recognized today as a form of inherited sudden cardiac arrest. The past 16 years witnessed a progressive increase in the number of reported cases and a dramatic proliferation of articles serving to define the clinical, genetic, cellular, ionic, and molecular aspects of the disease. This article provides a brief overview of recent advances in our understanding of the clinical presentation and molecular and cellular mechanisms and an update of existing controversies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Brugada P, Brugada J: Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome: a multicenter report. J Am Coll Cardiol 1992, 20:1391–1396.

    Article  PubMed  CAS  Google Scholar 

  2. Krishnan SC, Antzelevitch C: Sodium channel block produces opposite electrophysiological effects in canine ventricular epicardium and endocardium. Circ Res 1991, 69:277–291.

    PubMed  CAS  Google Scholar 

  3. Krishnan SC, Antzelevitch C: Flecainide-induced arrhythmia in canine ventricular epicardium. Phase 2 reentry? Circulation 1993, 87:562–572.

    PubMed  CAS  Google Scholar 

  4. Yan GX, Antzelevitch C: Cellular basis for the electrocardiographic J wave. Circulation 1996, 93:372–379.

    PubMed  CAS  Google Scholar 

  5. Miyazaki T, Mitamura H, Miyoshi S, et al.: Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome. J Am Coll Cardiol 1996, 27:1061–1070.

    Article  PubMed  CAS  Google Scholar 

  6. Wilde AA, Antzelevitch C, Borggrefe M, et al.: Proposed diagnostic criteria for the Brugada syndrome: consensus report. Circulation 2002, 106:2514–2519.

    Article  PubMed  Google Scholar 

  7. Antzelevitch C, Brugada P, Borggrefe M, et al.: Brugada Syndrome. Report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 2005, 111:659–670.

    Article  PubMed  Google Scholar 

  8. Chen Q, Kirsch GE, Zhang D, et al.: Genetic basis and molecular mechanisms for idiopathic ventricular fibrillation. Nature 1998, 392:293–296.

    Article  PubMed  CAS  Google Scholar 

  9. Antzelevitch C, Brugada P, Brugada J, et al.: The Brugada Syndrome: From Bench to Bedside. Oxford: Blackwell Futura; 2005.

    Google Scholar 

  10. Tan HL: Sodium channel variants in heart disease: expanding horizons. J Cardiovasc Electrophysiol 2006, 17(Suppl 1):S151–S157.

    Article  PubMed  Google Scholar 

  11. Hong K, Guerchicoff A, Pollevick GD, et al.: Cryptic 5′ splice site activation in SCN5A associated with Brugada syndrome. J Mol Cell Cardiol 2005, 38:555–560.

    Article  PubMed  CAS  Google Scholar 

  12. Bezzina CR, Shimizu W, Yang P, et al.: Common sodium channel promoter haplotype in Asian subjects underlies variability in cardiac conduction. Circulation 2006, 113:338–344.

    Article  PubMed  CAS  Google Scholar 

  13. Yang P, Koopmann TT, Pfeufer A, et al.: Polymorphisms in the cardiac sodium channel promoter displaying variant in vitro expression activity. Eur J Hum Genet 2008, 16:350–357.

    Article  PubMed  CAS  Google Scholar 

  14. London B, Michalec M, Mehdi H, et al.: Mutation in glycerol-3-phosphate dehydrogenase 1 like gene (GPD1-L) decreases cardiac Na+ current and causes inherited arrhythmias. Circulation 2007, 116:2260–2268.

    Article  PubMed  CAS  Google Scholar 

  15. Van Norstrand DW, Valdivia CR, Tester DJ, et al.: Molecular and functional characterization of novel glycerol-3-phosphate dehydrogenase 1 like gene (GPD1-L) mutations in sudden infant death syndrome. Circulation 2007, 116:2253–2259.

    Article  PubMed  CAS  Google Scholar 

  16. Skinner JR, Chung SK, Montgomery D, et al.: Near-miss SIDS due to Brugada syndrome. Arch Dis Child 2005, 90:528–529.

    Article  PubMed  CAS  Google Scholar 

  17. Antzelevitch C, Pollevick GD, Cordeiro JM, et al.: Loss-offunction mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation 2007, 115:442–449.

    Article  PubMed  Google Scholar 

  18. Cordeiro JM, Barajas-Martinez H, Hong K, et al.: Compound heterozygous mutations P336L and I1660V in the human cardiac sodium channel associated with the Brugada syndrome. Circulation 2006, 114:2026–2033.

    Article  PubMed  CAS  Google Scholar 

  19. Antzelevitch C: Brugada syndrome. Pacing Clin Electrophysiol 2006, 29:1130–1159.

    Article  PubMed  Google Scholar 

  20. Probst V, Denjoy I, Meregalli PG, et al.: Clinical aspects and prognosis of Brugada syndrome in children. Circulation 2007, 115:2042–2048.

    Article  PubMed  Google Scholar 

  21. Junttila MJ, Gonzalez M, Lizotte E, et al.: Induced Brugada-type electrocardiogram, a sign for imminent malignant arrhythmias. Circulation 2008, 117:1890–1893.

    Article  PubMed  Google Scholar 

  22. Wolpert C, Echternach C, Veltmann C, et al.: Intravenous drug challenge using flecainide and ajmaline in patients with Brugada syndrome. Heart Rhythm 2005, 2:254–260.

    Article  PubMed  Google Scholar 

  23. Peters S, Trummel M, Denecke S, et al.: Results of ajmaline testing in patients with arrhythmogenic right ventricular dysplasia-cardiomyopathy. Int J Cardiol 2004, 95:207–210.

    Article  PubMed  Google Scholar 

  24. Priori SG, Napolitano C: Management of patients with Brugada syndrome should not be based on programmed electrical stimulation. Circulation 2005, 112:285–291.

    Article  Google Scholar 

  25. Abello M, Merino JL, Peinado R, et al.: Negative flecainide test in Brugada syndrome patients with previous positive response. Europace 2006, 8:899–900.

    Article  PubMed  Google Scholar 

  26. Shimizu W, Matsuo K, Takagi M, et al.: Body surface distribution and response to drugs of ST segment elevation in Brugada syndrome: clinical implication of eighty-seven-lead body surface potential mapping and its application to twelve-lead electrocardiograms. J Cardiovasc Electrophysiol 2000, 11:396–404.

    Article  PubMed  CAS  Google Scholar 

  27. Miyamoto K, Yokokawa M, Tanaka K, et al.: Diagnostic and prognostic value of a type 1 Brugada electrocardiogram at higher (third or second) V1 to V2 recording in men with Brugada syndrome. Am J Cardiol 2007, 99:53–57.

    Article  PubMed  Google Scholar 

  28. Shin SC, Ryu S, Lee JH, et al.: Prevalence of the Brugada-type ECG recorded from higher intercostal spaces in healthy Korean males. Circ J 2005, 69:1064–1067.

    Article  PubMed  Google Scholar 

  29. Brugada J, Brugada R, Brugada P: Right bundle-branch block and ST-segment elevation in leads V1 through V3. A marker for sudden death in patients without demonstrable structural heart disease. Circulation 1998, 97:457–460.

    PubMed  CAS  Google Scholar 

  30. Brugada P, Brugada R, Brugada J: Patients with an asymptomatic Brugada electrocardiogram should undergo pharmacological and electrophysical testing. Circulation 2005, 112:279–285.

    Article  PubMed  Google Scholar 

  31. Brugada P, Brugada R, Brugada J: Response to Priori and Napolitano. Circulation 2005, 112:292.

    Article  Google Scholar 

  32. Eckardt L, Probst V, Smits JP, et al.: Long-term prognosis of individuals with right precordial ST-segment-elevation Brugada Syndrome. Circulation 2005, 111:257–263.

    Article  PubMed  Google Scholar 

  33. Gehi AK, Duong TD, Metz LD, et al.: Risk stratification of individuals with the Brugada electrocardiogram: a meta-analysis. J Cardiovasc Electrophysiol 2006, 17:577–583.

    Article  PubMed  Google Scholar 

  34. Ohkubo K, Watanabe I, Takagi Y, et al.: Electrocardiographic and electrophysiologic characteristics in patients with Brugada type electrocardiogram and inducible ventricular fibrillation. Circ J 2007, 71:1437–1441.

    Article  PubMed  Google Scholar 

  35. Paul M, Gerss J, Schulze-Bahr E, et al.: Role of programmed ventricular stimulation in patients with Brugada syndrome: a meta-analysis of worldwide published data. Eur Heart J 2007, 28:2126–2133.

    Article  PubMed  Google Scholar 

  36. Yan GX, Antzelevitch C: Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST segment elevation. Circulation 1999, 100:1660–1666.

    PubMed  CAS  Google Scholar 

  37. Fish JM, Antzelevitch C: Role of sodium and calcium channel block in unmasking the Brugada syndrome. Heart Rhythm 2004, 1:210–217.

    Article  PubMed  Google Scholar 

  38. Fish JM, Antzelevitch C: Cellular mechanism and arrhythmogenic potential of T-wave alternans in the Brugada syndrome. J Cardiovasc Electrophysiol 2008, 19:301–308.

    Article  PubMed  Google Scholar 

  39. Carlsson J, Erdogan A, Schulte B, et al.: Possible role of epicardial left ventricular programmed stimulation in Brugada syndrome. Pacing Clin Electrophysiol 2001, 24:247–249.

    Article  PubMed  CAS  Google Scholar 

  40. Junttila MJ, Brugada P, Hong K, et al.: Differences in 12-lead electrocardiogram between symptomatic and asymptomatic Brugada syndrome patients. J Cardiovasc Electrophysiol 2008, 19:380–383.

    Article  PubMed  Google Scholar 

  41. Meregalli PG, Ruijter JM, Hofman N, et al.: Diagnostic value of flecainide testing in unmasking SCN5A-related Brugada syndrome. J Cardiovasc Electrophysiol 2006, 17:857–864.

    Article  PubMed  Google Scholar 

  42. Sarkozy A, Boussy T, Kourgiannides G, et al.: Long-term follow-up of primary prophylactic implantable cardioverter-defibrillator therapy in Brugada syndrome. Eur Heart J 2007, 28:334–344.

    Article  PubMed  Google Scholar 

  43. Sacher F, Probst V, Iesaka Y, et al.: Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: a multicenter study. Circulation 2006, 114:2317–2324.

    Article  PubMed  Google Scholar 

  44. Bordachar P, Reuter S, Garrigue S, et al.: Incidence, clinical implications and prognosis of atrial arrhythmias in Brugada syndrome. Eur Heart J 2004, 25:879–884.

    Article  PubMed  Google Scholar 

  45. Francis J, Antzelevitch C: Atrial fibrillation and Brugada syndrome. J Am Coll Cardiol 2008, 51:1149–1153.

    Article  PubMed  Google Scholar 

  46. Babai Bigi MA, Aslani A, Shahrzad S: Clinical predictors of atrial fibrillation in Brugada syndrome. Europace 2007, 1:947–950.

    Article  Google Scholar 

  47. Kusano KF, Taniyama M, Nakamura K, et al.: Atrial fibrillation in patients with Brugada syndrome relationships of gene mutation, electrophysiology, and clinical backgrounds. J Am Coll Cardiol 2008, 51:1169–1175.

    Article  PubMed  Google Scholar 

  48. Viskin S: Brugada syndrome in children: don’t ask, don’t tell? Circulation 2007, 115:1970–1972.

    Article  PubMed  Google Scholar 

  49. Antzelevitch C, Brugada P, Brugada J, et al.: The Brugada Syndrome. Armonk, NY: Futura Publishing Company; 1999. [Clinical Approaches to Tachyarrhythmias Series, #10.]

    Google Scholar 

  50. Belhassen B, Viskin S: Pharmacologic approach to therapy of Brugada syndrome: quinidine as an alternative to ICD therapy? In The Brugada Syndrome: From Bench to Bedside. Edited by Antzelevitch C, Brugada P, Brugada J, Brugada R. Oxford: Blackwell Futura; 2004:202–211.

    Google Scholar 

  51. Ohgo T, Okamura H, Noda T, et al.: Acute and chronic management in patients with Brugada syndrome associated with electrical storm of ventricular fibrillation. Heart Rhythm 2007, 4:695–700.

    Article  PubMed  Google Scholar 

  52. Belardinelli L, Antzelevitch C, Vos MA: Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol Sci 2003, 24:619–625.

    Article  PubMed  CAS  Google Scholar 

  53. Antzelevitch C: Ionic, molecular, and cellular bases of QT-interval prolongation and torsade de pointes. Europace 2007, 9:iv4–iv15.

    Article  PubMed  Google Scholar 

  54. Marquez M, Salica G, Hermosillo AG, et al.: Ionic basis of pharmacological therapy in Brugada syndrome. J Cardiovasc Electrophysiol 2007, 18:234–240.

    Article  PubMed  Google Scholar 

  55. Tsuchiya T, Ashikaga K, Honda T, et al.: Prevention of ventricular fibrillation by cilostazol, an oral phosphodiesterase inhibitor, in a patient with Brugada syndrome. J Cardiovasc Electrophysiol 2002, 13:698–701.

    Article  PubMed  Google Scholar 

  56. Sergeev P, da Silva R, Lucchinetti E, et al.: Trigger-dependent gene expression profiles in cardiac preconditioning: evidence for distinct genetic programs in ischemic and anesthetic preconditioning. Anesthesiology 2004, 100:474–488.

    Article  PubMed  Google Scholar 

  57. Abud A, Bagattin D, Goyeneche R, et al.: Failure of cilostazol in the prevention of ventricular fibrillation in a patient with Brugada syndrome. J Cardiovasc Electrophysiol 2006, 17:210–212.

    Article  PubMed  Google Scholar 

  58. Fish JM, Welchons DR, Kim YS, et al.: Dimethyl lithospermate B, an extract of danshen, suppresses arrhythmogenesis associated with the Brugada syndrome. Circulation 2006, 113:1393–1400.

    Article  PubMed  CAS  Google Scholar 

  59. Haissaguerre M, Extramiana F, Hocini M, et al.: Mapping and ablation of ventricular fibrillation associated with long-QT and Brugada syndromes. Circulation 2003, 108:925–928.

    Article  PubMed  Google Scholar 

  60. Kataoka H: Electrocardiographic patterns of the Brugada syndrome in right ventricular infarction/ischemia. Am J Cardiol 2000, 86:1056.

    Article  PubMed  CAS  Google Scholar 

  61. Wang K, Asinger RW, Marriott HJ: ST-segment elevation in conditions other than acute myocardial infarction. N Engl J Med 2003, 349:2128–2135.

    Article  PubMed  CAS  Google Scholar 

  62. Myers GB: Other QRS-T patterns that may be mistaken for myocardial infarction. IV. Alterations in blood potassium; myocardial ischemia; subepicardial myocarditis; distortion associated with arrhythmias. Circulation 1950, 2:75–93.

    Google Scholar 

  63. Ortega-Carnicer J, Benezet J, Ruiz-Lorenzo F, et al.: Transient Brugada-type electrocardiographic abnormalities in renal failure reversed by dialysis. Resuscitation 2002, 55:215–219.

    Article  PubMed  Google Scholar 

  64. Douglas PS, Carmichael KA, Palevsky PM: Extreme hypercalcemia and electrocardiographic changes. Am J Cardiol 1984, 54:674–675.

    Article  PubMed  CAS  Google Scholar 

  65. Sridharan MR, Horan LG: Electrocardiographic J wave of hypercalcemia. Am J Cardiol 1984, 54:672–673.

    Article  PubMed  CAS  Google Scholar 

  66. Thiene G, Basso C, Calabrese F, et al.: Twenty years of progress and beckoning frontiers in cardiovascular pathology. Cardiovasc Pathol 2005, 14:165–169.

    Article  PubMed  CAS  Google Scholar 

  67. Hong K, Brugada J, Oliva A, et al.: Value of electrocardiographic parameters and ajmaline test in the diagnosis of Brugada syndrome caused by SCN5A mutations. Circulation 2004, 110:3023–3027.

    Article  PubMed  Google Scholar 

  68. Corrado D, Basso C, Buja G, et al.: Right bundle branch block, right precordial ST-segment elevation, and sudden death in young people. Circulation 2001, 103:710–717.

    PubMed  CAS  Google Scholar 

  69. Corrado D, Nava A, Buja G, et al.: Familial cardiomyopathy underlies syndrome of right bundle branch block, ST segment elevation and sudden death. J Am Coll Cardiol 1996, 27:443–448.

    Article  PubMed  CAS  Google Scholar 

  70. Abbott JA, Cheitlin MD: The nonspecific camel-hump sign. JAMA 1976, 235:413–414.

    Article  PubMed  CAS  Google Scholar 

  71. Hersch C: Electrocardiographic changes in head injuries. Circulation 1961, 23:853–860.

    PubMed  CAS  Google Scholar 

  72. Tarin N, Farre J, Rubio JM, et al.: Brugada-like electrocardiographic pattern in a patient with a mediastinal tumor. Pacing Clin Electrophysiol 1999, 22:1264–1266.

    Article  PubMed  CAS  Google Scholar 

  73. Atarashi H, Ogawa S: New ECG criteria for high-risk Brugada syndrome. Circ J 2003, 67:8–10.

    Article  PubMed  Google Scholar 

  74. Morita H, Takenaka-Morita S, Fukushima-Kusano K, et al.: Risk stratification for asymptomatic patients with Brugada syndrome. Circ J 2003, 67:312–316.

    Article  PubMed  Google Scholar 

  75. Takagi M, Tatsumi H, Yoshiyama M: Approach to the asymptomatic patients with Brugada syndrome. Indian Pacing Electrophysiol J 2007, 7:73–76.

    PubMed  Google Scholar 

  76. Bigi MA, Aslani A, Aslani A: Significance of cardiac autonomic neuropathy in risk stratification of Brugada syndrome. Europace 2007 Dec 18 (Epub ahead of print).

  77. Castro Hevia J, Antzelevitch C, Tornés Bárzaga F, et al.: Tpeak-Tend and Tpeak-Tend dispersion as risk factors for ventricular tachycardia/ventricular fibrillation in patients with the Brugada syndrome. J Am Coll Cardiol 2006, 47:1828–1834.

    Article  PubMed  Google Scholar 

  78. Nishizaki M, Fujii H, Sakurada H, et al.: Spontaneous T wave alternans in a patient with Brugada syndrome-responses to intravenous administration of class I antiarrhythmic drug, glucose tolerance test, and atrial pacing. J Cardiovasc Electrophysiol 2005, 16:217–220.

    Article  PubMed  Google Scholar 

  79. Tada H, Nogami A, Shimizu W, et al.: ST segment and T wave alternans in a patient with Brugada syndrome. Pacing Clin Electrophysiol 2000, 23:413–415.

    Article  PubMed  CAS  Google Scholar 

  80. Chinushi M, Washizuka T, Okumura H, et al.: Intravenous administration of class I antiarrhythmic drugs induced T wave alternans in a patient with Brugada syndrome. J Cardiovasc Electrophysiol 2001, 12:493–495.

    Article  PubMed  CAS  Google Scholar 

  81. Chinushi Y, Chinushi M, Toida T, et al.: Class I antiarrhythmic drug and coronary vasospasm-induced T wave alternans and ventricular tachyarrhythmia in a patient with Brugada syndrome and vasospastic angina. J Cardiovasc Electrophysiol 2002, 13:191–194.

    Article  PubMed  Google Scholar 

  82. Takagi M, Doi A, Takeuchi K, et al.: Pilsicanide-induced marked T wave alternans and ventricular fibrillation in a patient with Brugada syndrome. J Cardiovasc Electrophysiol 2002, 13:837.

    Article  PubMed  Google Scholar 

  83. Ohkubo K, Watanabe I, Okumura Y, et al.: Intravenous administration of class I antiarrhythmic drug induced T wave alternans in an asymptomatic Brugada syndrome patient. Pacing Clin Electrophysiol 2003, 26:1900–1903.

    Article  PubMed  Google Scholar 

  84. Morita H, Morita ST, Nagase S, et al.: Ventricular arrhythmia induced by sodium channel blocker in patients with Brugada syndrome. J Am Coll Cardiol 2003, 42:1624–1631.

    Article  PubMed  CAS  Google Scholar 

  85. Morita H, Nagase S, Kusano K, et al.: Spontaneous T wave alternans and premature ventricular contractions during febrile illness in a patient with Brugada syndrome. J Cardiovasc Electrophysiol 2002, 13:816–818.

    Article  PubMed  Google Scholar 

  86. Tada T, Kusano KF, Nagase S, et al.: Clinical significance of macroscopic T-wave alternans after sodium channel blocker administration in patients with Brugada syndrome. J Cardiovasc Electrophysiol 2008, 19:56–61.

    Article  PubMed  Google Scholar 

  87. Babai Bigi MA, Aslani A, Shahrzad S: aVR sign as a risk factor for life-threatening arrhythmic events in patients with Brugada syndrome. Heart Rhythm 2007, 4:1009–1012.

    Article  PubMed  Google Scholar 

  88. Babaee Bigi MA, Moaref AR, Aslani A: Interventricular mechanical dyssynchrony: a novel marker of cardiac events in Brugada syndrome. Heart Rhythm 2008, 5:79–82.

    Article  PubMed  Google Scholar 

  89. Watanabe H, Koopmann TT, Le Scouarnec S, et al.: Sodium channel beta1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans. J Clin Invest 2008, 118:2260–2268.

    PubMed  CAS  Google Scholar 

  90. Delpón E, Cordeiro JM, Núñez L, et al.: Functional effects of KCNE3 mutation and its role in the development of Brugada syndrome. Circulation Arrhythmia and Electrophysiology 2008 (in press).

Download references

Author information

Authors and Affiliations

  1. Gordon K. Moe Scholar, Masonic Medical Research Laboratory, 2150 Bleecker Street, Utica, NY, 13501, USA

    Charles Antzelevitch

Authors
  1. Charles Antzelevitch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eyal Nof
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Charles Antzelevitch.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Antzelevitch, C., Nof, E. Brugada syndrome: Recent advances and controversies. Curr Cardiol Rep 10, 376–383 (2008). https://doi.org/10.1007/s11886-008-0060-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11886-008-0060-y

Keywords

Search

Navigation